enGene Holdings Inc., a clinical-stage genetic medicines company, has appointed Amy Pott as Chief Global Commercialization Officer. Ms. Pott will lead commercialization planning and execution, reporting to CEO Ron Cooper. This move comes as enGene prepares to file a Biologics License Application for its lead investigational agent in bladder cancer treatment. Prior to joining enGene, Ms. Pott held senior roles at Astellas Pharma, Swedish Orphan Biovitrum, Shire, and Baxalta, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.